• Alda 1: Practical ALDH2 Activator Workflows

  2026-08-31

  Alda 1 provides a research-ready way to probe ALDH2-dependent aldehyde detoxification, cardioprotection in ischemia, and stress-response biology. Its activity toward both ALDH2*1 and ALDH2*2 supports genotype-aware assays, while its compatibility with cellular and animal models enables workflows ranging from enzyme kinetics to pressure-overload studies.

• Telmisartan in Cardiac Hypertrophy Research

  2026-08-31

  Use Telmisartan as a defined AT1-receptor perturbation tool in angiotensin II-driven hypertrophy models, then separate upstream receptor effects from downstream RIP3/CaMKII biology. This workflow combines solvent-aware preparation, orthogonal phenotyping, and practical controls for cardiovascular disease research.

• Dye Models for Small Tissue Biopsies in Pathology

  2026-08-30

  The reference study evaluated five dyes as visibility aids for 0.2–0.3 cm tissue samples during surgical pathology processing. Merbromin, hematoxylin, and alcian blue improved sample observability, but hematoxylin provided the most favorable balance of visibility, lower toxicity, and compatibility with routine slide interpretation.

• Azilsartan medoxomil monopotassium Workflow

  2026-08-29

  Build more interpretable AT1-receptor assays and translational blood pressure models with TAK 491. This workflow emphasizes DMSO control, washout design, concentration selection, and mechanism-linked readouts for hypertension and cardiovascular research.

• Angiotensin II: From GPCR Signaling to Translation

  2026-08-28

  A thought-leadership guide to using Angiotensin II as a defined perturbation for vascular, inflammatory, and remodeling studies. It connects receptor-proximal signaling with macrophage biology, experimental design, and translational decision-making.

• VERTIS CV: Ertugliflozin Cardiovascular Outcomes

  2026-08-28

  The VERTIS CV trial tested whether ertugliflozin provided cardiovascular safety and benefit in patients with type 2 diabetes and established atherosclerotic cardiovascular disease. Ertugliflozin met the prespecified noninferiority criterion for major adverse cardiovascular events, while effects on heart-failure and renal composites were directionally favorable but not statistically superior.

• Angiotensin II Workflows for Vascular Research

  2026-08-28

  Build reproducible Angiotensin II experiments that move from acute GPCR signaling to chronic vascular and atrial remodeling models. This workflow connects dose preparation, time-resolved readouts, and troubleshooting with findings from a hypertension-associated atrial fibrillation study.

• How Manufacturing Tunes LNP Size and mRNA Expression

  2026-08-27

  The reference study shows that modest changes in the aqueous-to-organic phase ratio during microfluidic lipid nanoparticle production can tune particle dimensions and alter mRNA expression. Its results also demonstrate that the relationship between LNP size and expression depends on the biological system, with distinct responses in HEK293 cells, THP-1 cells, and BALB/c mice.

• Rifampin Workflows for Transcriptional Control

  2026-08-27

  Build reproducible Rifampin experiments for bacterial transcription shutoff, resistance mapping, RNA-decay measurements, and synthetic biology controls. The article also explains how these workflows complement, but do not replace, the light-inducible translational switch described in the 2026 Trends in Biotechnology study.

• Angiotensin II: Practical Research Protocol

  2026-08-26

  Angiotensin II (SKU A1042) provides a defined octapeptide stimulus for studying GPCR-linked vascular signaling, oxidative responses, hypertension mechanisms, and vascular remodeling. It is intended for controlled research workflows only; it should not be used as a diagnostic or therapeutic material, and prepared solutions are not suitable for long-term storage.

• Quercetin: From PI3K Signaling to Ferroptosis

  2026-08-26

  Quercetin is emerging as more than a conventional flavonoid probe. Its established relevance to PI3K signaling, NF-κB, mitochondrial apoptosis, p53, and cell cycle regulation now intersects with evidence that it can suppress ferroptotic liver injury through the ACSL4/LPCAT3/ALOX15 axis in Wilson’s disease models. This article translates those findings into a practical framework for cancer research and disease-oriented assay design.

• 7-Ethyl-10-hydroxycamptothecin: Research Workflow

  2026-08-25

  Build reproducible colon cancer experiments around SN-38 with a workflow that connects topoisomerase I trapping, S-phase and G2 phase arrest, apoptosis, and FUBP1–FUSE disruption. The guide combines practical dosing, assay selection, stability controls, and troubleshooting for advanced cancer research.

• Tacalcitol Induces NGF in Human Keratinocytes

  2026-08-24

  The reference study showed that tacalcitol, a synthetic analog of vitamin D3, induces nerve growth factor (NGF) production and NGF mRNA expression in the human epidermal keratinocyte line K-TL-1. Its time-dependent and dose-dependent effects provide a mechanistic rationale for studying vitamin D signaling in cutaneous nerve support, while remaining preliminary for peripheral neuropathy treatment.

• LNP Entrapment, Trafficking, and Endosomal Escape

  2026-08-24

  This study shows that lipid nanoparticle delivery depends not only on cellular uptake but also on where internalized particles travel within the endolysosomal system. By combining sensitive LNP labeling with controlled endolysosomal states, the authors identify peripheral endosome entrapment as a barrier to perinuclear trafficking and cytosolic cargo release, while linking sustained internalization and lysosomal accumulation with productive delivery.

• Fosinopril sodium in ACE Research

  2026-08-23

  Fosinopril sodium connects mechanistic ACE inhibition with oral, cardiovascular, and renal study designs. Its prodrug activation, phosphinic acid zinc binding, and dual elimination profile help researchers build more translational hypertension workflows while avoiding common formulation and interpretation errors.

450 records 6/30 page Previous Next First page 上5页 678910 下5页 Last page